{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T01:04:13Z","timestamp":1780707853204,"version":"3.54.1"},"reference-count":14,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2001,2,1]],"date-time":"2001-02-01T00:00:00Z","timestamp":980985600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2001,2,1]],"date-time":"2001-02-01T00:00:00Z","timestamp":980985600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2001,2]]},"DOI":"10.1067\/mjd.2001.101885","type":"journal-article","created":{"date-parts":[[2002,7,25]],"date-time":"2002-07-25T00:18:43Z","timestamp":1027556323000},"page":"354-357","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":63,"special_numbering":"P2","title":["Stevens-Johnson syndrome caused by the antiretroviral drug nevirapine"],"prefix":"10.1067","volume":"44","author":[{"given":"Denise W.","family":"Metry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Lahart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn L.","family":"Farmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adelaide A.","family":"Hebert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1067\/mjd.2001.101885_bib1","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S0140-6736(98)24008-6","article-title":"Nevirapine-associated Stevens-Johnson syndrome","volume":"351","author":"Warren","year":"1998","journal-title":"Lancet"},{"key":"10.1067\/mjd.2001.101885_bib2","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/S0149-2918(98)80105-7","article-title":"Safety profile of nevirapine, a non-nucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection","volume":"20","author":"Pollard","year":"1998","journal-title":"Clin Ther"},{"key":"10.1067\/mjd.2001.101885_bib3","article-title":"Gender differences in nevirapine rash","author":"Bersoff-Matcha","year":"1999"},{"key":"10.1067\/mjd.2001.101885_bib4","article-title":"Prednisone during the induction phase of nevirapine therapy appears to reduce the incidence of nevirapine-associated rash","author":"Kaspar","year":"1998"},{"key":"10.1067\/mjd.2001.101885_bib5","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1097\/00002030-199903110-00013","article-title":"Incidence of rash and discontinuation of nevirapine using two different escalating initial doses","volume":"13","author":"Anton","year":"1999","journal-title":"AIDS"},{"key":"10.1067\/mjd.2001.101885_bib6","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1128\/AAC.43.3.603","article-title":"Safety and pharmacokinetics of abacavir (1592U89) following oral administration of escalating single doses in human immunodeficiency virus type 1-infected adults","volume":"43","author":"Kumar","year":"1999","journal-title":"Antimicrobial Agents Chemother"},{"key":"10.1067\/mjd.2001.101885_bib7","first-page":"634","article-title":"Stevens-Johnson syndrome caused by indinavir","volume":"30","author":"Teira","year":"1999","journal-title":"Scand J Infect Dis"},{"key":"10.1067\/mjd.2001.101885_bib8","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1093\/clinids\/23.3.640","article-title":"Fatal toxic epidermolysis induced by zidovudine","volume":"23","author":"Murri","year":"1996","journal-title":"Clin Infect Dis"},{"key":"10.1067\/mjd.2001.101885_bib9","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/0140-6736(92)92740-7","article-title":"Didanosine as probable cause of Stevens-Johnson syndrome","volume":"340","author":"Parneix-Spake","year":"1992","journal-title":"Lancet"},{"key":"10.1067\/mjd.2001.101885_bib10","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(96)91459-2","article-title":"Hypersensitivity syndrome associated with zalcitabine therapy","volume":"347","author":"Tancrede-Bohin","year":"1996","journal-title":"Lancet"},{"key":"10.1067\/mjd.2001.101885_bib11","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/00002030-199503000-00001","article-title":"Pathogenesis of hypersensitivity reactions to drugs in patients with HIV infection: Allergic or toxic?","volume":"9","author":"Koopmans","year":"1995","journal-title":"AIDS"},{"key":"10.1067\/mjd.2001.101885_bib12","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/j.1365-2230.1997.tb01038.x","article-title":"Increased drug reactions in HIV-1 positive patients: a possible explanation based on patterns of immune dysregulation seen in HIV-1 disease","volume":"22","author":"Smith","year":"1997","journal-title":"Clin Exp Dermatol"},{"key":"10.1067\/mjd.2001.101885_bib13","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1046\/j.1365-2133.1999.02850.x","article-title":"Nevirapine-induced overlap Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"140","author":"Wetterwald","year":"1999","journal-title":"Br J Dermatol"},{"key":"10.1067\/mjd.2001.101885_bib14","series-title":"The Physicians' Desk Reference","first-page":"2768","year":"1999"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962201760070?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962201760070?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T21:24:01Z","timestamp":1759267441000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962201760070"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,2]]},"references-count":14,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2001,2]]}},"alternative-id":["S0190962201760070"],"URL":"https:\/\/doi.org\/10.1067\/mjd.2001.101885","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2001,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stevens-Johnson syndrome caused by the antiretroviral drug nevirapine","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1067\/mjd.2001.101885","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2001 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}